SHR-A1811 for Solid Tumors

Mary Crowley Cancer Research, Dallas, TX
Solid TumorsSHR-A1811 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it is safe and effective against HER2-expressing solid tumors.

Eligible Conditions
  • Advanced Solid Tumors

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Through study completion, an average of 1 year

Day 90
Incidence and severity of adverse events (AEs)
Month 30
Tumor response using RECIST 1.1
Year 1
Immunogenicity of SHR-A1811
PK parameter: AUC0-t of SHR-A1811
PK parameter: Cmax of SHR-A1811
PK parameter: Tmax of SHR-A1811

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Part 1 Dose escalation
1 of 2
Part 2 Indication expansion
1 of 2

Experimental Treatment

226 Total Participants · 2 Treatment Groups

Primary Treatment: SHR-A1811 · No Placebo Group · Phase 1

Part 1 Dose escalation
Drug
Experimental Group · 1 Intervention: SHR-A1811 · Intervention Types: Drug
Part 2 Indication expansion
Drug
Experimental Group · 1 Intervention: SHR-A1811 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

Jiangsu HengRui Medicine Co., Ltd.Lead Sponsor
577 Previous Clinical Trials
87,918 Total Patients Enrolled
Atridia Pty Ltd.Industry Sponsor
24 Previous Clinical Trials
786 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Is this research initiative currently seeking participants?

"As per clinicaltrials.gov, the search for participants in this medical trial is still underway. It was first published on September 3rd 2020 with its most recent update occurring on December 22nd 2021." - Anonymous Online Contributor

Unverified Answer

How widely distributed is the trial being conducted in this metropolitan area?

"Patients can participate in this study at the Mary Crowley Cancer Research centre located in Dallas, Montefiore-Einstein Center for Cancer Care situated within Bronx, and Gabrail Cancer Research Center based out of Canton; there are 2 other sites as well." - Anonymous Online Contributor

Unverified Answer

What is the aggregate sum of participants in this trial?

"This research necessitates the recruitment of 226 qualified individuals to participate in this medical trial. Candidates can join from Mary Crowley Cancer Research (Texas) or Montefiore-Einstein Center for Cancer Care (New York)." - Anonymous Online Contributor

Unverified Answer

What dangers have been associated with utilization of SHR-A1811?

"Our assessment of SHR-A1811's safety was marked at 1, as this is a preliminary trial with limited evidence for both efficacy and safety." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.